<DOC>
	<DOCNO>NCT02942160</DOCNO>
	<brief_summary>A Phase 2 , Open-Label Extension Study EN3835 Treatment Edematous Fibrosclerotic Panniculopathy ( commonly know Cellulite ) .</brief_summary>
	<brief_title>EN3835 Treatment Edematous Fibrosclerotic Panniculopathy ( Commonly Known Cellulite )</brief_title>
	<detailed_description />
	<mesh_term>Edema</mesh_term>
	<criteria>Inclusion Criteria Observation Phase : Voluntarily sign date inform consent agreement Have participate complete doubleblind study EN3835201 Be willing apply sunscreen treat quadrant exposure sun Inclusion Criteria Treatment Phase : Voluntarily sign date inform consent agreement Have participate complete doubleblind study EN3835201 Be willing apply sunscreen treat quadrant exposure sun Have least 1 quadrant : score 3 4 ( moderate severe ) report PCSS ( Photonumeric Cellulite Severity Scale ) subject investigator , Hexsel CSS ( Cellulite Severity Scale ) score great 13 Be judge good health Have negative urine pregnancy test screen use effective contraception method , surgically sterile , postmenopausal Exclusion Criteria Observation Phase : Exclusion Criteria Treatment Phase : Has use , intend use course study , treatment EFP leg buttock Is presently nursing baby provide breast milk baby Intends become pregnant study Currently receiving , receive within 7 day injection study drug , plan receive anticoagulant antiplatelet medication History stroke bleed</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>